1. Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study
- Author
-
Adrianna Murphy, PhD, Benjamin Palafox, MSc, Owen O'Donnell, ProfPhD, David Stuckler, ProfPhD, Pablo Perel, PhD, Khalid F AlHabib, ProfMBBS, Alvaro Avezum, ProfPhD, Xiulin Bai, BSc, Jephat Chifamba, ProfDPhil, Clara K Chow, ProfPhD, Daniel J Corsi, PhD, Gilles R Dagenais, MD, Antonio L Dans, MD, Rafael Diaz, MD, Ayse N Erbakan, MD, Noorhassim Ismail, MD, Romaina Iqbal, PhD, Roya Kelishadi, MD, Rasha Khatib, PhD, Fernando Lanas, PhD, Scott A Lear, ProfPhD, Wei Li, ProfPhD, Jia Liu, MSc, Patricio Lopez-Jaramillo, ProfPhD, Viswanathan Mohan, ProfMD, Nahed Monsef, PhD, Prem K Mony, MD, Thandi Puoane, ProfDrPH, Sumathy Rangarajan, MSc, Annika Rosengren, ProfMD, Aletta E Schutte, ProfPhD, Mariz Sintaha, MSc, Koon K Teo, ProfPhD, Andreas Wielgosz, ProfMD, Karen Yeates, MD, Lu Yin, PhD, Khalid Yusoff, ProfMBBS, Katarzyna Zatońska, PhD, Salim Yusuf, ProfPhD, and Martin McKee, ProfPhD
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
Summary: Background: There is little evidence on the use of secondary prevention medicines for cardiovascular disease by socioeconomic groups in countries at different levels of economic development. Methods: We assessed use of antiplatelet, cholesterol, and blood-pressure-lowering drugs in 8492 individuals with self-reported cardiovascular disease from 21 countries enrolled in the Prospective Urban Rural Epidemiology (PURE) study. Defining one or more drugs as a minimal level of secondary prevention, wealth-related inequality was measured using the Wagstaff concentration index, scaled from −1 (pro-poor) to 1 (pro-rich), standardised by age and sex. Correlations between inequalities and national health-related indicators were estimated. Findings: The proportion of patients with cardiovascular disease on three medications ranged from 0% in South Africa (95% CI 0–1·7), Tanzania (0–3·6), and Zimbabwe (0–5·1), to 49·3% in Canada (44·4–54·3). Proportions receiving at least one drug varied from 2·0% (95% CI 0·5–6·9) in Tanzania to 91·4% (86·6–94·6) in Sweden. There was significant (p
- Published
- 2018
- Full Text
- View/download PDF